RegeneRx Files with FDA for Second
Selected Abstract
RegeneRx Files with FDA for Second Phase II Clinical Trial; European Trial to Study TB4 In Patients with Venous Stasis Ulcers.
BETHESDA, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTCBB:RGRX) (www.regenerx.com) announced that it has filed with the FDA to initiate a Phase II clinical trial to test its drug, Thymosin beta 4 (TB4), for the treatment of venous stasis ulcers. This will be our second Phase II trial evaluating the ... December 20, 2004; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
RegeneRx Files with FDA for Second Phase II Clinical Trial; European Trial to Study TB4 In Patients with Venous Stasis Ulcers.
|
